These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 21887710)

  • 1. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
    Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
    Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.
    Jackson CE; Gronseth G; Rosenfeld J; Barohn RJ; Dubinsky R; Simpson CB; McVey A; Kittrell PP; King R; Herbelin L;
    Muscle Nerve; 2009 Feb; 39(2):137-43. PubMed ID: 19145653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
    Ondo WG; Hunter C; Moore W
    Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease.
    Contarino MF; Pompili M; Tittoto P; Vanacore N; Sabatelli M; Cedrone A; Rapaccini GL; Gasbarrini G; Tonali PA; Bentivoglio AR
    Parkinsonism Relat Disord; 2007 Jul; 13(5):299-303. PubMed ID: 16807056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial.
    Alrefai AH; Aburahma SK; Khader YS
    Clin Neurol Neurosurg; 2009 Jan; 111(1):79-82. PubMed ID: 18977585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
    Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Dorsch U; Csikós J; Blitzer A
    Parkinsonism Relat Disord; 2020 Jan; 70():23-30. PubMed ID: 31794936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins.
    Narayanaswami P; Geisbush T; Tarulli A; Raynor E; Gautam S; Tarsy D; Gronseth G
    Parkinsonism Relat Disord; 2016 Sep; 30():73-7. PubMed ID: 27406786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
    Mancini F; Zangaglia R; Cristina S; Sommaruga MG; Martignoni E; Nappi G; Pacchetti C
    Mov Disord; 2003 Jun; 18(6):685-8. PubMed ID: 12784273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses.
    Basciani M; Di Rienzo F; Fontana A; Copetti M; Pellegrini F; Intiso D
    Dev Med Child Neurol; 2011 Jun; 53(6):559-64. PubMed ID: 21413974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea.
    Steinlechner S; Klein C; Moser A; Lencer R; Hagenah J
    Psychopharmacology (Berl); 2010 Jan; 207(4):593-7. PubMed ID: 19823807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
    Wilken B; Aslami B; Backes H
    Neuropediatrics; 2008 Aug; 39(4):200-4. PubMed ID: 19165707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    J Neurol; 2009 Apr; 256(4):563-7. PubMed ID: 19401804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence.
    Schroeder AS; Kling T; Huss K; Borggraefe I; Koerte IK; Blaschek A; Jahn K; Heinen F; Berweck S
    Neuropediatrics; 2012 Feb; 43(1):27-36. PubMed ID: 22430158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis.
    Verma A; Steele J
    Muscle Nerve; 2006 Aug; 34(2):235-7. PubMed ID: 16583370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
    Nóbrega AC; Rodrigues B; Torres AC; Enzo A; Melo A
    J Neurol Sci; 2007 Feb; 253(1-2):85-7. PubMed ID: 17229441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
    Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR
    Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients.
    Lloret SP; Nano G; Carrosella A; Gamzu E; Merello M
    J Neurol Sci; 2011 Nov; 310(1-2):248-50. PubMed ID: 21636098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety study.
    Trosch RM; Adler CH; Pappert EJ
    Mov Disord; 2007 Jul; 22(9):1258-64. PubMed ID: 17588242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.